Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;31(2):135-146.
doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11.

CAR T cell therapy for B-cell lymphomas

Julio C Chavez  1 , Frederick L Locke  2
Affiliations
Review

CAR T cell therapy for B-cell lymphomas

Julio C Chavez et al. Best Pract Res Clin Haematol. 2018 Jun.

Abstract

B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.

Keywords: Aggressive lymphomas; CART; Diffuse large B cell lymphoma; Immunotherapy; Refractory.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

Julio C. Chavez: Kite Pharma (Advisory Board, Speakers Bureau), Novartis (Advisory Board), Genentech (Speakers Bureau), Frederick F. Locke: Kite Pharma (Scientific Advisor), Cellular Biomedicine Group (Consultant).

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–90. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
    1. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 2015;90(9):790–5. - PubMed
    1. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9(3):279–86. - PubMed
    1. Geldres C, Savoldo B, Dotti G. Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol 2016;28(1):3–9. - PMC - PubMed

MeSH terms